A New lung adenocarcinoma Adenocarcinoma Treatment! National Cancer Center Develops Innovative Analysis Method

No effective treatment has been found for about 30% of lung adenocarcinoma patients

Lung adenocarcinoma is the most common type of lung cancer, and the number of patients has been increasing in recent years. However, for "driver gene-positive" lung adenocarcinoma caused by genetic mutations such as EGFR and KRAS, there is an effective treatment called molecular targeted therapy (anticancer drug).

On the other hand, about 30% of lung adenocarcinoma patients cannot receive molecular targeted therapy because these driver gene mutations are not found. For these patients, there is an urgent need to develop new treatment methods.
Therefore, we are informing you below of a method that is said to be promising at this time.

Innovative Analysis Method Developed by the National Cancer Center

The National Cancer Center has developed a new analysis method using whole genome sequencing to solve this issue. This method enables the discovery of genetic abnormalities that have been missed by conventional analysis methods, and is expected to lead to the discovery of new therapeutic targets for driver gene-negative lung adenocarcinoma.

Key points of the research

Focus on super-enhancers and genomic structural abnormalities: We focused on "super-enhancers," which strongly promote gene expression, and "genomic structural abnormalities," which are abnormalities in chromosome structure, which have been difficult to capture using conventional analysis methods.

Realization of large-scale analysis using robotics technology: By using humanoid robots, we realized highly reproducible and efficient large-scale analysis.

Research Results

We found that super-enhancer and genomic structural abnormalities coexist in approximately 40% of driver gene-negative lung adenocarcinomas.

In addition to known oncogenes such as HER2 and EGFR, genes such as FRS2, CAV2, FGF3, FGF4, and FGF19 were suggested to function as causative genes in lung cancer.

It was suggested that a specific group of genes may influence lung adenocarcinoma progression and therapeutic response.

Future Prospects

The results of this study are expected not only to lead to the discovery of new therapeutic targets for driver gene-negative lung adenocarcinoma, but also to contribute to improving the accuracy of diagnosis and prognosis prediction of lung adenocarcinoma.

The National Cancer Center will continue to develop this research to further advance the treatment of lung adenocarcinoma patients.
As more data is collected and used in the future, a treatment method for all lung adenocarcinoma patients may be found.
We look forward to not only foreign technology but also Japanese technology.